In May, Elevar and Hengrui Pharma submitted an NDA and BLA for the combination of rivoceranib and camrelizumab as a first-line therapy for uHCC, with FDA PDUFA dates in May 2024 Fort Lee, N.J., and Princeton, N.J., Oct. 17, 2023
Fort Lee, New Jersey, Sept. 21, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,
Fort Lee, New Jersey, September 19, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,
Fort Lee, N.J., Aug. 15, 2023 — Elevar Therapeutics, Inc., majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced
Fort Lee, New Jersey, August 3, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,
In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progression-free survival, and improved overall response rate versus sorafenib, a standard first-line treatment for uHCC Fort Lee, New Jersey, July 24, 2023 – Elevar Therapeutics,
With a standard review, FDA set a PDUFA target action date of May 16, 2024 FORT LEE, NEW JERSEY, July 17, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. And a fully integrated biopharmaceutical company dedicated to
FORT LEE, NEW JERSEY, June 1, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,
Fort Lee, N.J., May 17, 2023 – Elevar Therapeutics, Inc., a wholly owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,
Orlando, Fla., April 18, 2023 – Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that a comparative biochemical analysis identified rivoceranib, its
